Here's What Analysts Are Forecasting For Yatharth Hospital & Trauma Care Services Limited (NSE:YATHARTH) After Its Second-Quarter Results

Last week, you might have seen that Yatharth Hospital & Trauma Care Services Limited (NSE:YATHARTH) released its second-quarter result to the market. The early response was not positive, with shares down 9.9% to ₹611 in the past week. Yatharth Hospital & Trauma Care Services reported in line with analyst predictions, delivering revenues of ₹2.2b and statutory earnings per share of ₹14.46, suggesting the business is executing well and in line with its plan. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Check out our latest analysis for Yatharth Hospital & Trauma Care Services

Taking into account the latest results, the most recent consensus for Yatharth Hospital & Trauma Care Services from four analysts is for revenues of ₹9.16b in 2025. If met, it would imply a meaningful 18% increase on its revenue over the past 12 months. Statutory per share are forecast to be ₹15.30, approximately in line with the last 12 months. Before this earnings report, the analysts had been forecasting revenues of ₹9.06b and earnings per share (EPS) of ₹17.00 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

The consensus price target held steady at ₹662, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Yatharth Hospital & Trauma Care Services, with the most bullish analyst valuing it at ₹790 and the most bearish at ₹517 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Yatharth Hospital & Trauma Care Services shareholders.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Yatharth Hospital & Trauma Care Services' growth to accelerate, with the forecast 38% annualised growth to the end of 2025 ranking favourably alongside historical growth of 27% per annum over the past year. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Yatharth Hospital & Trauma Care Services to grow faster than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Yatharth Hospital & Trauma Care Services. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹662, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Yatharth Hospital & Trauma Care Services analysts - going out to 2027, and you can see them free on our platform here.

Plus, you should also learn about the 1 warning sign we've spotted with Yatharth Hospital & Trauma Care Services .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.